Note20182017Underlying£mNon-underlying*(notes4 & 5)£mTotal£mUnderlying£mNon-underlying*(notes4 & 5)£mTotal£mRevenue2407.1—407.1359.3—359.3Cost of sales(179.6)(5.1)(184.7)(163.4)(4.2)(167.6)Gross profit227.5(5.1)222.4195.9(4.2)191.7Selling, general and administrative expenses(110.0)(52.0)(162.0)(99.6)(32.5)(132.1)Research and development expenses(18.3)(8.0)(26.3)(15.0)(11.4)(26.4)Operating profit299.2(65.1)34.181.3(48.1)33.2Finance income31.5—1.50.8—0.8Finance expense4(6.9)0.5(6.4)(5.1)(0.2)(5.3)Share of loss of investments accounted for using the equity method6(0.1)(0.2)(0.3)—(0.1)(0.1)Profit before taxation793.7(64.8)28.977.0(48.4)28.6Income taxes9(19.2)26.47.2(16.9)14.4(2.5)Profit for the year74.5(38.4)36.160.1(34.0)26.1Attributable to:Owners of the parent74.5(38.4)36.160.1(34.0)26.1Non-controlling interests27——————Profit for the year74.5(38.4)36.160.1(34.0)26.1Earnings per shareBasic1137.24p28.09pDiluted1137.04p27.93pDividend per share (interim paid and final proposed for the year)1025.50p21.44pNon-underlying items comprise items associated with areas such as amortisation and related costs of acquired intangibles, impairment of investments, remeasurement and other movements on deferred and contingent consideration, non-cash inventory adjustments, rationalisation of manufacturing organisation costs, rationalisation and acquisition expenses, loss on extinguishment of debt and fair value and taxation credits. prev Independent Auditor's Report to the Members of Dechra Pharmaceuticals PLC next Consolidated Statement of Comprehensive Income